# Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)

Study · id `cardio:ct-nct01704261` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01704261](<https://clinicaltrials.gov/study/NCT01704261>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01704261

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 307 participants.

## Technical summary

Registry record NCT01704261. Randomized; triple masking; primary purpose treatment. Start 2012-10-18 (actual); primary completion 2014-12-23 (actual). Results posted on 2015-11-25.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 307 participants (enrolled count; ClinicalTrials.gov record NCT01704261, source copy `cardio:ctgov-nct01704261-2018-09-10`, retrieved 2026-10-26)
- Started: 2012-10-18 (actual) (ClinicalTrials.gov record NCT01704261, source copy `cardio:ctgov-nct01704261-2018-09-10`, retrieved 2026-10-26)
- Primary completion: 2014-12-23 (actual) (ClinicalTrials.gov record NCT01704261, source copy `cardio:ctgov-nct01704261-2018-09-10`, retrieved 2026-10-26)
- Completion: 2014-12-23 (actual) (ClinicalTrials.gov record NCT01704261, source copy `cardio:ctgov-nct01704261-2018-09-10`, retrieved 2026-10-26)
- Results first posted: 2015-11-25 (ClinicalTrials.gov record NCT01704261, source copy `cardio:ctgov-nct01704261-2018-09-10`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01704261-2018-09-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Omarigliptin
- Intervention (Drug): Matching placebo to Omarigliptin
- Intervention (Drug): Glimepiride
- Intervention (Drug): Metformin
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin (`cardio:pubmed-29110647`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 4190608a62f44420df16badd282f186c3dffd3f97d106db7c881545ff572b5f3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
